Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese

被引:32
作者
Hishida, A
Matsuo, K
Tajima, K
Ogura, M
Kagami, Y
Taji, H
Morishima, Y
Emi, N
Naoe, T
Hamajima, N
机构
[1] Nagoya Univ, Dept Mol Med & Clin Sci, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Dept Hematol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Aichi Canc Ctr, Div Epidemiol, Nagoya, Aichi 464, Japan
[4] Aichi Canc Ctr, Div Prevent, Nagoya, Aichi 464, Japan
[5] Aichi Canc Ctr, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan
[6] Nagoya Univ, Dept Prevent Med Biostat & Med Decis Making, Grad Sch Med, Nagoya, Aichi, Japan
关键词
p53 Ar72Pro polymorphism; p73 dinucleotide polymorphism; p21 Ser31Arg polymorphism; non-Hodgkin's lymphoma; genetic predisposition to disease;
D O I
10.1080/10428190310001638878
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We hypothesized that the polymorphisms in the two p53 family genes ( p53 Arg72Pro and p73 G4C14- to- A4T14 at exon 2 (G4A)) and p21 Ser31Arg polymorphism might modulate the risk of non-Hodgkin's lymphoma, and conducted a hospital-based prevalent case - control study at Aichi Cancer Center Hospital to clarify the association. Risk estimation for each genotype by the unconditional logistic model demonstrated the possible association between the p53 Pro72 allele and the risk of non-Hodgkin's lymphoma in Japanese population(OR = 1.59; 95% CI, 0.99 - 2.57, P= 0.057), although no other significant association was observed. The analyses of statistical interactions between these three polymorphisms ( p73 G4A, p53 Arg72Pro and p21 Ser31Arg polymorphisms) revealed the marginally significant OR for interaction between p53 Arg72Pro and p73 G4A polymorphisms (OR = 2.54; 95% CI, 0.97 - 6.62, P= 0.057). When those without p53 Pro72 and p73 A4T14 alleles were defined as a reference, those with p53 Pro72 and p73 A4T14 alleles demonstrated a significantly higher OR (2.08; 95% CI, 1.11 - 3.90, P= 0.023). Further examination with a sufficiently larger population and other ethnicities are required to confirm our findings.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 49 条
[1]   Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers:: Prevalence of alterations in inflammatory breast cancers [J].
Ahomadegbe, JC ;
Tourpin, S ;
Kaghad, M ;
Zelek, L ;
Vayssade, M ;
Mathieu, MC ;
Rochard, F ;
Spielmann, M ;
Tursz, T ;
Caput, D ;
Riou, G ;
Bénard, J .
ONCOGENE, 2000, 19 (47) :5413-5418
[2]   The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas [J].
Andersson, S ;
Rylander, E ;
Strand, A ;
Sällström, J ;
Wilander, E .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1153-1156
[3]   SMOKING AND RISK OF NON-HODGKINS-LYMPHOMA AND MULTIPLE-MYELOMA [J].
BROWN, LM ;
EVERETT, GD ;
GIBSON, R ;
BURMEISTER, LF ;
SCHUMAN, LM ;
BLAIR, A .
CANCER CAUSES & CONTROL, 1992, 3 (01) :49-55
[4]   p21 gene codon 31 polymorphism is associated with bladder cancer [J].
Chen, WC ;
Wu, HC ;
Hsu, CD ;
Chen, HY ;
Tsai, FJ .
UROLOGIC ONCOLOGY, 2002, 7 (02) :63-66
[5]   Diet and risk of non-Hodgkin lymphoma in older women [J].
Chiu, BCH ;
Cerhan, JR ;
Folsom, AR ;
Sellers, TA ;
Kushi, LH ;
Wallace, RB ;
Zheng, W ;
Potter, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (17) :1315-1321
[6]   Blood transfusions as a risk factor for non-Hodgkin's lymphoma in the San Francisco Bay area: A population-based study [J].
Chow, EJ ;
Holly, EA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (08) :725-731
[7]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[8]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[9]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[10]  
Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037